Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

DEC reported for 2023 by RAS

3/7/24 DVEC

MTS business in Armenia sold $209.1 mln

3/7/24 MTSS

Head of Inter RAO will leave the company in the near future

3/7/24 IRAO

LSR majority shareholder Andrei Molchanov resigned as CEO

3/6/24 LSRG

Gazprom neft started development of the Chonskoye cluster

3/6/24 SIBN

HeadHunter redomiciles from Cyprus to Kaliningrad ATS

3/6/24 HEAD

Headhunter hints at dividends

3/6/24 HEAD

Headhunter has reported for 2023

3/6/24 HEAD

LSR minority shareholders may demand to buy back their securities at ₽1260 per share

3/6/24 LSRG

RusHydro reported for 2023 by IFRS

3/6/24 HYDR